Researchers reported new molecular insights into C5aR2, a complement receptor described as having atypical signaling behavior compared with classical complement pathways. The work outlines how C5aR2 relates to C5aR1 and the inflammatory effects driven by the anaphylatoxin C5a. Because complement signaling is implicated in inflammation and immune dysregulation across multiple therapeutic areas, characterizing unique receptor signaling can influence target selection and drug development strategies. The report frames C5aR2’s distinct role as long unclear due to its nontraditional signaling characteristics. This study broadens mechanistic understanding that could support downstream efforts in designing receptor-specific modulators or refining combination strategies with other complement components.